paperId
stringlengths
13
45
doi
stringlengths
13
45
title
stringlengths
1
377
publicationYear
int64
1.85k
2.03k
publicationDate
stringlengths
4
10
type
stringclasses
18 values
publisher
stringclasses
232 values
containerTitle
stringlengths
3
149
volume
stringclasses
308 values
issue
stringclasses
204 values
page
stringlengths
1
13
issn
stringlengths
9
20
isbn
stringclasses
204 values
authors
stringlengths
2
37.4k
authorCount
int64
0
2.93k
firstAuthorAffiliation
stringlengths
5
506
isReferencedByCount
int64
0
67.6k
referenceCount
int64
0
1.6k
isOpenAccess
bool
2 classes
licenseUrl
stringclasses
67 values
funderNames
stringclasses
364 values
funderIds
stringclasses
303 values
url
stringlengths
29
61
pdfUrl
stringlengths
37
152
abstract
stringlengths
0
4.36k
subject
null
language
stringclasses
5 values
_run_id
stringclasses
50 values
_dataset_id
stringclasses
50 values
10.1093/oncolo/oyag155
10.1093/oncolo/oyag155
KRAS G12R in pancreatic cancer: why this mutation resists current inhibitor strategies
2,026
2026-06-06
journal-article
Oxford University Press (OUP)
The Oncologist
31
7
null
1083-7159, 1549-490X
null
Kenneth A Kern
1
Affiliate Faculty, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego , San Diego, CA 92109,
0
48
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1093/oncolo/oyag155
https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyag155/68446122/oyag155.pdf
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal solid malignancies, with limited therapeutic progress despite decades of cytotoxic chemotherapy. About 90% of PDAC tumors harbor activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS), making oncogenic KRAS ...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1535-7163.targ-15-b90
10.1158/1535-7163.targ-15-b90
Abstract B90: HSP90 inhibitor NVP-AUY922 sensitizes intrinsic MEK inhibitor Trametinib-resistant NSCLC cells harboring KRAS mutation
2,015
2015-12-01
journal-article
American Association for Cancer Research (AACR)
Molecular Cancer Therapeutics
14
12_Supplement_2
B90-B90
1535-7163, 1538-8514
null
Dae Ho Lee, Kang-Seo Park, Bora Oh, Mi-Hee Lee, Hannah Yang
5
1Univ. of Ulsan Asan Medical Ctr., Seoul, Korea, Republic of;
0
0
true
null
null
null
https://doi.org/10.1158/1535-7163.targ-15-b90
https://aacrjournals.org/mct/article/14/12_Supplement_2/B90/232668/Abstract-B90-HSP90-inhibitor-NVP-AUY922-sensitizes
Abstract Introduction: Mutant KRAS is feature of more than 25% of non-small cell lung cancers (NSCLC) and exemplifies one of the most popular oncogenic drivers. Ras-driven tumors are often hard to cure with conventional therapies and are necessary novel treatment strategies. Experiment: Using the HSP90 inhibitor NVP-AU...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.2174/0929867329666220907161505
10.2174/0929867329666220907161505
Sotorasib: First Approved <i>KRAS</i> Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer
2,023
2023-03
journal-article
Bentham Science Publishers Ltd.
Current Medicinal Chemistry
30
9
1000-1002
0929-8673
null
Surya K. De
1
Conju-probe, San Diego, California, USA
5
20
true
null
null
null
https://doi.org/10.2174/0929867329666220907161505
https://www.eurekaselect.com/article/download?doi=10.2174/0929867329666220907161505
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/2159-8290.cd-rw2023-090
10.1158/2159-8290.cd-rw2023-090
A Pan-KRAS Inhibitor Impedes Common KRAS Oncoproteins and Tumor Growth
2,023
2023-08-04
journal-article
American Association for Cancer Research (AACR)
Cancer Discovery
13
8
1757-1757
2159-8274, 2159-8290
null
null
0
null
3
0
true
null
null
null
https://doi.org/10.1158/2159-8290.cd-rw2023-090
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-RW2023-090/727234/A-Pan-KRAS-Inhibitor-Impedes-Common-KRAS
Abstract A pan-KRAS inhibitor is selec­tive for the inactive state of multiple KRAS mutants, sparing other RAS isoforms.
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1093/ajcp/aqaf121.447
10.1093/ajcp/aqaf121.447
20 Beyond KRAS G12D Mutation: The Prognostic Significance of The KRAS Mutation Variants on Progression-Free Survival in Pancreatic Ductal Adenocarcinoma
2,025
2025-11-01
journal-article
Oxford University Press (OUP)
American Journal of Clinical Pathology
164
Supplement_1
null
0002-9173, 1943-7722
null
Ahmed Younes, Haider Mejbel
2
Emory University School of Medicine
0
0
true
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
null
null
https://doi.org/10.1093/ajcp/aqaf121.447
https://academic.oup.com/ajcp/article-pdf/164/Supplement_1/aqaf121.447/65271120/aqaf121.447.pdf
Abstract Pancreatic ductal adenocarcinomas (PDACs) are aggressive neoplasms with poor outcomes. The prognostic significance of major driver gene mutation, beyond KRAS G12D, is yet to be explored. A 10-year retrospective comprehensive study of the prognostic significance of major driver genes in PDACs was conducted. Nex...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1111/joim.13057
10.1111/joim.13057
Targeting Kras<sup>g12c</sup>‐mutant cancer with a mutation‐specific inhibitor
2,020
2020-08
journal-article
Wiley
Journal of Internal Medicine
288
2
183-191
0954-6820, 1365-2796
null
J. G. Christensen, P. Olson, T. Briere, C. Wiel, M. O. Bergo
5
From the Mirati Therapeutics, Inc. San Diego CA USA
69
38
true
http://onlinelibrary.wiley.com/termsAndConditions#vor
null
null
https://doi.org/10.1111/joim.13057
https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjoim.13057
AbstractThe RAS genes, which include H, N, and KRAS, comprise the most frequently mutated family of oncogenes in cancer. Mutations in KRAS – such as the G12C mutation – are found in most pancreatic, half of colorectal and a third of lung cancer cases and is thus responsible for a substantial proportion of cancer deaths...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1007/s00280-023-04545-4
10.1007/s00280-023-04545-4
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
2,023
2023-08
journal-article
Springer Science and Business Media LLC
Cancer Chemotherapy and Pharmacology
92
2
107-118
0344-5704, 1432-0843
null
Sarina A. Piha-Paul, Chieh Tseng, Hai T. Tran, Meng Gao, Daniel D. Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D. Kawedia, Siqing Fu, Shubham Pant, Timothy A. Yap, Van K. Morris, Bryan K. Kee, Mariela Blum Murphy, JoAnn Lim, Funda Meric-Bernstam
16
null
7
42
true
https://creativecommons.org/licenses/by/4.0
Puma Biotechnology
10.13039/100019402
https://doi.org/10.1007/s00280-023-04545-4
https://link.springer.com/content/pdf/10.1007/s00280-023-04545-4.pdf
Abstract Purpose Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberrant or compensatory mechanisms. Herein, we sought to determine the feasibility and safety of neratinib a...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.c.7429504
10.1158/1078-0432.c.7429504
Data from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.c.7429504
null
&lt;div&gt;AbstractPurpose:&lt;p&gt;To inform prognosis, treatment response, disease biology, and &lt;i&gt;KRAS G12C&lt;/i&gt; mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a &lt;i&gt;KRAS G12C&lt;/i&gt; mutation treated with single-...
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1535-7163.targ-09-c108
10.1158/1535-7163.targ-09-c108
Abstract C108: A novel mitotic kinesin Eg5 inhibitor exerts the growth-inhibitory effect in cancer cells in a manner independent of induction of monoastral formation but dependent of KRAS mutation status
2,009
2009-12-10
journal-article
American Association for Cancer Research (AACR)
Molecular Cancer Therapeutics
8
12_Supplement
C108-C108
1535-7163, 1538-8514
null
Toshimitsu Tanaka
1
Shizuoka Cancer Center Research Institute, Suntou-gun, Japan.
0
0
true
null
null
null
https://doi.org/10.1158/1535-7163.targ-09-c108
https://aacrjournals.org/mct/article/8/12_Supplement/C108/237744/Abstract-C108-A-novel-mitotic-kinesin-Eg5
Abstract Mitotic kinesin Eg5 plays an important role in mitosis, as it is critical for proper bipolar spindle assembly. After the discovery of the first Eg5 inhibitor monastrol, a number of Eg5 inhibitors have been developed as anticancer drugs. We have previously synthesized a series of S-trityl-L-cysteine (STLC) deri...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.c.7429504.v1
10.1158/1078-0432.c.7429504.v1
Data from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.c.7429504.v1
null
&lt;div&gt;AbstractPurpose:&lt;p&gt;To inform prognosis, treatment response, disease biology, and &lt;i&gt;KRAS G12C&lt;/i&gt; mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a &lt;i&gt;KRAS G12C&lt;/i&gt; mutation treated with single-...
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1200/jco.2012.30.15_suppl.e14102
10.1200/jco.2012.30.15_suppl.e14102
KRAS mutation profile in Puerto Rican patients with colorectal cancer: Trends in expression of KRAS mutation in PR between April 2009 to January 2011.
2,012
2012-05-20
journal-article
American Society of Clinical Oncology (ASCO)
Journal of Clinical Oncology
30
15_suppl
e14102-e14102
0732-183X, 1527-7755
null
Yelitza Ruiz, Christine Miranda, Robert F. Hunter
3
PRHOG, Bayamon, PR
0
0
false
null
null
null
https://doi.org/10.1200/jco.2012.30.15_suppl.e14102
null
e14102 Background: The prevalence of a mutated KRAS gene in colorectal cancer shows ethnic variation with a range between 30-48% among the Caucasian, Asian, and European populations. The purpose of this study was to define the profile of KRAS mutation in colorectal cancer patients in Puerto Rico. Methods: Between April...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1538-7445.am2022-2667
10.1158/1538-7445.am2022-2667
Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation
2,022
2022-06-15
journal-article
American Association for Cancer Research (AACR)
Cancer Research
82
12_Supplement
2667-2667
1538-7445
null
Irene C. Waizenegger, Hengyu Lu, Claus Thamer, Fabio Savarese, Daniel Gerlach, Dorothea Rudolph, Christopher P. Vellano, Marcelo Marotti, John Heymach, Scott Kopetz, Timothy P. Heffernan, Joseph R. Marszalek, Mark P. Petronczki, Marco H. Hofmann, Norbert Kraut
15
1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria;
19
0
true
null
null
null
https://doi.org/10.1158/1538-7445.am2022-2667
https://aacrjournals.org/cancerres/article/82/12_Supplement/2667/699883/Abstract-2667-Trial-in-progress-Phase-1-study-of
Abstract Inhibition of KRASG12C mediated signaling and the therapeutic impact in non-small cell lung cancer (NSCLC) whose tumors carry this mutation was demonstrated clinically by sotorasib and adagrasib leading to approval of sotorasib in KRASG12C mutant NSCLC. These encouraging data are currently changing the treatme...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926606.v1
10.1158/1078-0432.26926606.v1
Supplementary Figure S3 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926606.v1
null
&lt;p&gt;Supplementary Figure S3&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.21203/rs.3.rs-1675918/v1
10.21203/rs.3.rs-1675918/v1
Differences in gene mutation profiles of colon cancer patients with or without a KRAS mutation
2,022
2022-06-03
posted-content
Research Square Platform LLC
null
null
null
null
null
null
Shujian Chang, Yudan Zhou, Ruirong Wu, Xiaosong Ge, Yong Pu
5
Affiliated Hospital of Jiangnan University
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.21203/rs.3.rs-1675918/v1
null
Abstract RAS plays an important role in the carcinogenesis of colorectal epithelial cells, but RAS mutations are only present, at most, in approximately 50% of patients. In order to compare the gene mutation profiles of patients with or without a KRAS mutation, the clinicopathological data of 858 patients and NGS test ...
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926615
10.1158/1078-0432.26926615
GO42144 INVESTIGATORS AND STUDY GROUP1 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926615
null
&lt;p&gt;GO42144 INVESTIGATORS AND STUDY GROUP&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926597
10.1158/1078-0432.26926597
Supplementary Table S1 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926597
null
&lt;p&gt;Representativeness of Study Participants&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926600
10.1158/1078-0432.26926600
Supplementary Figure S5 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926600
null
&lt;p&gt;Supplementary Figure S5&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926609
10.1158/1078-0432.26926609
Supplementary Figure S2 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926609
null
&lt;p&gt;Supplementary Figure S2&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926597.v1
10.1158/1078-0432.26926597.v1
Supplementary Table S1 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926597.v1
null
&lt;p&gt;Representativeness of Study Participants&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/2159-8290.cd-nb2019-092
10.1158/2159-8290.cd-nb2019-092
Researchers Reveal Another KRAS Inhibitor
2,019
2019-09-01
journal-article
American Association for Cancer Research (AACR)
Cancer Discovery
9
9
1152-1152
2159-8274, 2159-8290
null
null
0
null
3
0
true
null
null
null
https://doi.org/10.1158/2159-8290.cd-nb2019-092
https://aacrjournals.org/cancerdiscovery/article-pdf/9/9/1152/1847633/1152.pdf
Abstract Researchers have developed a KRAS inhibitor, BI-2852, that inhibits ERK phosphorylation and reduces proliferation of KRAS-mutant cancer cells. A drug based on the molecule may be effective in patients who don't respond to the KRASG12C inhibitors currently in clinical trials.
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926600.v1
10.1158/1078-0432.26926600.v1
Supplementary Figure S5 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926600.v1
null
&lt;p&gt;Supplementary Figure S5&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926609.v1
10.1158/1078-0432.26926609.v1
Supplementary Figure S2 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926609.v1
null
&lt;p&gt;Supplementary Figure S2&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1538-7445.am2014-lb-209
10.1158/1538-7445.am2014-lb-209
Abstract LB-209: Chromatin condensation in KRAS-mutant lung cancer as a therapeutic target: challenging the paradigm of associating KRAS mutation with EGFR inhibitor resistance
2,014
2014-10-01
journal-article
American Association for Cancer Research (AACR)
Cancer Research
74
19_Supplement
LB-209-LB-209
0008-5472, 1538-7445
null
Meng Wang, Ashley M. Kern, Marieke Hülskötter, Patricia Greninger, Anurag Singh, Yunfeng Pan, Dipanjan Chowdhury, Mechthild Krause, Michael Baumann, Cyril H. Benes, Jason A. Efstathiou, Jeff Settleman, Henning Willers
13
1Department of Radiation Oncology, Mass. General Hospital, Boston, MA;
0
0
true
null
null
null
https://doi.org/10.1158/1538-7445.am2014-lb-209
https://aacrjournals.org/cancerres/article/74/19_Supplement/LB-209/598543/Abstract-LB-209-Chromatin-condensation-in-KRAS
Abstract Non-small cell lung cancer (NSCLC) with mutations in the KRAS oncogene is generally resistant to targeted agents directed against the epidermal growth factor receptor (EGFR). Although EGFR is active in KRAS-mutant cancers its role in supporting cell survival and its potential utility as a therapeutic target ha...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926615.v1
10.1158/1078-0432.26926615.v1
GO42144 INVESTIGATORS AND STUDY GROUP1 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926615.v1
null
&lt;p&gt;GO42144 INVESTIGATORS AND STUDY GROUP&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926603
10.1158/1078-0432.26926603
Supplementary Figure S4 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926603
null
&lt;p&gt;Supplementary Figure S4&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926612
10.1158/1078-0432.26926612
Supplementary Figure S1 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926612
null
&lt;p&gt;Supplementary Figure S1&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926606
10.1158/1078-0432.26926606
Supplementary Figure S3 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926606
null
&lt;p&gt;Supplementary Figure S3&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/2159-8290.cd-nb2021-0335
10.1158/2159-8290.cd-nb2021-0335
Mechanisms of KRAS Inhibitor Resistance Revealed
2,021
2021-06-01
journal-article
American Association for Cancer Research (AACR)
Cancer Discovery
11
6
1311-1312
2159-8274, 2159-8290
null
null
0
null
6
0
true
null
null
null
https://doi.org/10.1158/2159-8290.cd-nb2021-0335
https://aacrjournals.org/cancerdiscovery/article-pdf/11/6/1311/3104989/1311.pdf
Abstract A recent study revealed diverse mechanisms of acquired resistance in patients with non–small cell lung cancer or colorectal cancer who stop responding to a KRASG12C inhibitor. These patients developed secondary KRAS mutations, MAPK pathway alterations, or genomic rearrangements—and in some cases multiple resis...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1538-7445.am2025-6390
10.1158/1538-7445.am2025-6390
Abstract 6390: Identification of novel pan-KRAS mutation inhibitor shows significant efficacy in pancreatic cancer with no toxicity, offering hope beyond current therapies
2,025
2025-04-21
journal-article
American Association for Cancer Research (AACR)
Cancer Research
85
8_Supplement_1
6390-6390
0008-5472, 1538-7445
null
Pinar Atalay, Asli Ture, Nermin Kahraman, Izabela Fokt, Waldemar Priebe, Erdem Buyukbingol, Bulent Ozpolat
7
1Houston Methodist Research Institute, Houston, TX;
1
0
true
null
null
null
https://doi.org/10.1158/1538-7445.am2025-6390
https://aacrjournals.org/cancerres/article/85/8_Supplement_1/6390/761122/Abstract-6390-Identification-of-novel-pan-KRAS
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging cancers to treat, with current therapies providing a median survival of just six months. The intrinsic chemoresistance and genetic heterogeneity of PDAC tumors complicate the development of effective targeted therapies. Approximately 90% of...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926612.v1
10.1158/1078-0432.26926612.v1
Supplementary Figure S1 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926612.v1
null
&lt;p&gt;Supplementary Figure S1&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.26926603.v1
10.1158/1078-0432.26926603.v1
Supplementary Figure S4 from Circulating Tumor DNA Dynamics Reveal &lt;i&gt;KRAS G12C&lt;/i&gt; Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2,024
2024-09-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi
15
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.26926603.v1
null
&lt;p&gt;Supplementary Figure S4&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1538-7445.am2026-2441
10.1158/1538-7445.am2026-2441
Abstract 2441: The myCAF and ECM landscape in KRAS-mutated cancer: Utilizing liquid biomarkers to track KRAS-induced fibrosis and KRAS inhibitor efficacy
2,026
2026-04-03
journal-article
American Association for Cancer Research (AACR)
Cancer Research
86
7_Supplement
2441-2441
0008-5472, 1538-7445
null
Martin Birkmose Rasmussen, Rasmus Sund Pedersen, Nicholas Willumsen, Morten Karsdal
4
Nordic Bioscience, Copenhagen, Denmark.
0
0
true
null
null
null
https://doi.org/10.1158/1538-7445.am2026-2441
https://aacrjournals.org/cancerres/article/86/7_Supplement/2441/778838/Abstract-2441-The-myCAF-and-ECM-landscape-in-KRAS
Abstract Background: KRAS-driven cancer represents ∼25% of cancers, with high rates in pancreatic cancer (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). Mutated KRAS and TGF-β signaling activate cancer-associated fibroblasts (CAFs), creating a fibrotic extracellular matrix (ECM). The fibrotic E...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.4103/crst.crst_145_21
10.4103/crst.crst_145_21
Sotorasib – an inhibitor of KRAS p.G12c mutation in advanced non-small cell carcinoma
2,021
2021-07
journal-article
Medknow
Cancer Research, Statistics, and Treatment
4
3
524-528
2590-3233
null
Amit Kumar Agrawal, Ramya Pragya, Amit Choudhary, Anuj Gupta, Kuraparthy Sambasivaiah, Bal Krishna Mishra, Satvik Khaddar, Akhil Kapoor
8
null
9
21
true
null
null
null
https://doi.org/10.4103/crst.crst_145_21
null
The KRAS p.G12C mutation occurs in seen in 13% of non-small cell lung cancers (NSCLCs) and in approximately 1%–3% of colorectal and other cancers. Until the last decade, there were no approved therapies for targeting the KRAS mutation, but recently, drugs targeting the mutation have been discovered. KRAS is a small pro...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/2159-8290.cd-nb2020-098
10.1158/2159-8290.cd-nb2020-098
Another KRAS Inhibitor Holds Its Own
2,020
2020-12-01
journal-article
American Association for Cancer Research (AACR)
Cancer Discovery
10
12
OF2-OF2
2159-8274, 2159-8290
null
null
0
null
9
0
true
null
null
null
https://doi.org/10.1158/2159-8290.cd-nb2020-098
https://aacrjournals.org/cancerdiscovery/article/10/12/OF2/2593/Another-KRAS-Inhibitor-Holds-Its-OwnAnother-KRAS
Abstract According to the KRYSTAL-1 study, the KRASG12c inhibitor adagrasib, also known as MRTX849, is largely well tolerated and shows considerable efficacy in patients with non–small cell lung cancer harboring this mutation. The drug is also active, albeit more modestly, in colorectal cancer and several other solid t...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/2159-8290.cd-nb2021-0362
10.1158/2159-8290.cd-nb2021-0362
FDA Approves First KRAS Inhibitor: Sotorasib
2,021
2021-08-01
journal-article
American Association for Cancer Research (AACR)
Cancer Discovery
11
8
OF4-OF4
2159-8274, 2159-8290
null
null
0
null
39
0
true
null
null
null
https://doi.org/10.1158/2159-8290.cd-nb2021-0362
https://aacrjournals.org/cancerdiscovery/article/11/8/OF4/666268/FDA-Approves-First-KRAS-Inhibitor-SotorasibFDA
Abstract The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In a phase II trial, the drug yielded a median progression-free survival of 6.8 months in patients whose disease had advanced despite treatment with standard...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.31466/kfbd.981849
10.31466/kfbd.981849
Comparison of KRAS Mutation Status with Clinical Parameters in Colon Adenocarcinoma
2,021
2021-12-15
journal-article
Karadeniz Fen Bilimleri Dergisi
Karadeniz Fen Bilimleri Dergisi
11
2
648-662
2564-7377
null
Barış BOYLU, Mustafa TÜRKMEN
2
Giresun Üniversitesi
0
38
false
null
null
null
https://doi.org/10.31466/kfbd.981849
null
KRAS mutations are mutually exclusive with other activating mutations on EGFR pathway. Detection of KRAS mutations associated with tumorigenesis, predicates the lack of other mutations on the same pathway and shows that the application of targeted therapy approaches which target other proteins in EGFR-MAPK pathway inef...
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/2159-8290.cd-nb2020-089
10.1158/2159-8290.cd-nb2020-089
KRAS Inhibitor Continues to Impress in NSCLC
2,020
2020-11-01
journal-article
American Association for Cancer Research (AACR)
Cancer Discovery
10
11
1617-1617
2159-8274, 2159-8290
null
null
0
null
3
0
true
null
null
null
https://doi.org/10.1158/2159-8290.cd-nb2020-089
https://aacrjournals.org/cancerdiscovery/article-pdf/10/11/1617/1816282/1617.pdf
Abstract Evidence continues to grow that KRAS, once considered an “undruggable” target, can be targeted successfully in non–small cell lung cancer. In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.26434/chemrxiv.15002376/v1
10.26434/chemrxiv.15002376/v1
D33E mutation reshapes active and inactive conformations of KRAS
2,026
2026-04-24
posted-content
American Chemical Society (ACS)
null
null
null
null
null
null
Nicholas A. Carton, Maxim Mulligan, Brajesh Narayan, Nicolae-Viorel Buchete
4
School of Physics
0
0
true
null
null
null
https://doi.org/10.26434/chemrxiv.15002376/v1
null
GTP-bound KRAS cycles between inactive and active conformations through coordinated rearrangements of Switch I and Switch II, yet the structural and kinetic consequences of many clinically observed mutations remain unresolved. The rare D33E substitution lies within the electrostatic network of Switch I and, despite bei...
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.70389/pjs.100001
10.70389/pjs.100001
Targeting the Undruggable KRAS Mutation in Lung Cancer: A Review
2,024
2024-10-27
journal-article
Premier Science
Premier Journal of Science
null
null
null
3049-9011
null
Clark Jones
1
Pharmaceutical Scientist and Molecular Biologist
0
32
true
http://creativecommons.org/licenses/by/3.0/deed.en_US
null
null
https://doi.org/10.70389/pjs.100001
null
Targeting the KRAS mutation in lung cancer has proven to be a challenging yet essential task due to its intricate signaling mechanisms and high prevalence in non-small cell lung cancer (NSCLC). Despite historical setbacks, recent advancements have led to the approval of targeted therapies such as sotorasib and adagrasi...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.c.8630813
10.1158/1078-0432.c.8630813
Data from The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with &lt;i&gt;KRAS&lt;/i&gt; Mutation-Positive Solid Tumors
2,026
2026-08-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Pasi A. Jänne, Melissa L. Johnson, Jin Li, Shubham Pant, Ulrich Dünzinger, Luis Ilia, Kerstin Möldner, Jae Eui Soh, Noboru Yamamoto
9
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.c.8630813
null
&lt;div&gt;Abstract Purpose:&lt;p&gt;BI 1701963 is a small-molecule son of sevenless 1 (SOS1) inhibitor that selectively binds to SOS1, blocking the protein–protein interaction of SOS1 with guanosine diphosphate-bound rat sarcoma virus (RAS) proteins [Kirsten RAS (KRAS), Harvey RAS, and neuroblastoma RAS], thereby inhi...
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1101/2022.12.16.520846
10.1101/2022.12.16.520846
A non-conserved histidine residue on KRAS drives paralog selectivity of the KRAS G12D inhibitor MRTX1133
2,022
2022-12-19
posted-content
openRxiv
null
null
null
null
null
null
Miles A. Keats, John J. W. Han, Yeon-Hwa Lee, Chih-Shia Lee, Ji Luo
5
null
1
15
true
null
null
null
https://doi.org/10.1101/2022.12.16.520846
null
Abstract The discovery of small molecule inhibitors against mutant KRAS protein was a recent breakthrough in targeted therapy. Understanding the mechanism of selectivity by KRAS inhibitors and the mechanism of resistance to them can guide the future development of KRAS inhibitors. MRTX1133 was the first non-covalent in...
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/2159-8290.cd-rw2021-167
10.1158/2159-8290.cd-rw2021-167
Resistant KRAS(G12C) Inhibitor Subclones Exhibit Heterogeneous Alterations
2,022
2022-01-01
journal-article
American Association for Cancer Research (AACR)
Cancer Discovery
12
1
13-13
2159-8274, 2159-8290
null
null
0
null
0
0
true
null
null
null
https://doi.org/10.1158/2159-8290.cd-rw2021-167
https://aacrjournals.org/cancerdiscovery/article-pdf/12/1/13/3019863/13a.pdf
Abstract KRAS(G12C) inhibitor (G12Ci) resistance exhibits a heterogeneous pattern with no one dominant alteration.
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.33143537
10.1158/1078-0432.33143537
Supplementary Table S4 from The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with &lt;i&gt;KRAS&lt;/i&gt; Mutation-Positive Solid Tumors
2,026
2026-08-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Pasi A. Jänne, Melissa L. Johnson, Jin Li, Shubham Pant, Ulrich Dünzinger, Luis Ilia, Kerstin Möldner, Jae Eui Soh, Noboru Yamamoto
9
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.33143537
null
&lt;p&gt;Supplementary Table S4: Pharmacokinetic parameters of BI 1701963 monotherapy (Studies NCT04111458, NCT04835714 and NCT04627142)&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.3390/cancers17071237
10.3390/cancers17071237
Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation
2,025
2025-04-05
journal-article
MDPI AG
Cancers
17
7
1237
2072-6694
null
Martin Faehling, Sabine Fallscheer, Birgit Schwenk, Harald Seifarth, Jörn Sträter, Claudia Lengerke, Petros Christopoulos
7
Clinic of Cardiology and Pneumology, Esslingen Hospital, 73730 Esslingen, Germany
2
56
true
https://creativecommons.org/licenses/by/4.0/
German Cancer Consortium
10.13039/501100012353
https://doi.org/10.3390/cancers17071237
null
Background: Treatment of lung adenocarcinoma has changed and now includes checkpoint inhibitors (CPIs) or, in the case of an EGFR mutation, third-generation EGFR TKI osimertinib. Few data compare the long-term overall survival (OS) of current and historic subgroups. Methods: This real-world analysis (KOMPASS study) inc...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.33143549
10.1158/1078-0432.33143549
Supplementary Figure S2 from The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with &lt;i&gt;KRAS&lt;/i&gt; Mutation-Positive Solid Tumors
2,026
2026-08-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Pasi A. Jänne, Melissa L. Johnson, Jin Li, Shubham Pant, Ulrich Dünzinger, Luis Ilia, Kerstin Möldner, Jae Eui Soh, Noboru Yamamoto
9
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.33143549
null
&lt;p&gt;Supplementary Figure S2. Ki67 Proliferative Index from tumor biopsies taken at screening and at Day 16 of Cycle 1 in patients treated in NCT04111458&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1538-7445.am2019-2197
10.1158/1538-7445.am2019-2197
Abstract 2197: The AXL kinase inhibitor, TP-0903, demonstrates efficacy in preclinical models of colorectal cancer independent of KRAS mutation status
2,019
2019-07-01
journal-article
American Association for Cancer Research (AACR)
Cancer Research
79
13_Supplement
2197-2197
0008-5472, 1538-7445
null
Ryan Mangelson, Peter Peterson, Jason M. Foulks, Yuta Matsumura, Lars Mouritsen, Clifford J. Whatcott, David J. Bearss, Steven L. Warner
8
Tolero Pharmaceuticals, Inc., Lehi, UT.
3
0
true
null
null
null
https://doi.org/10.1158/1538-7445.am2019-2197
https://aacrjournals.org/cancerres/article/79/13_Supplement/2197/634210/Abstract-2197-The-AXL-kinase-inhibitor-TP-0903
Abstract Colorectal cancer (CRC) is the third leading cause of cancer-related mortality in the US (2017). Most patients present with stage II or III disease at diagnosis, with the 5-year survival rate between 53-89%. Survival in patients with stage IV CRC, however, is a discouraging 11%. Metastasis in CRC is linked to ...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.20944/preprints202105.0471.v1
10.20944/preprints202105.0471.v1
The KRAS G12C mutation in NSCLC: from target to resistance
2,021
2021-05-20
posted-content
MDPI AG
null
null
null
null
null
null
Alfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
3
null
15
0
true
http://creativecommons.org/licenses/by/4.0
null
null
https://doi.org/10.20944/preprints202105.0471.v1
null
Lung cancer represents the most common form of cancer accounting for 1.8 million deaths globally in 2020.The 5-year relative survival rate for lung cancer is lower than many other leading cancer types. Over the last decade the treatment for advanced and metastatic non small cell lung cancer have dramatically improved d...
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.33143552
10.1158/1078-0432.33143552
Supplementary Figure S1 from The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with &lt;i&gt;KRAS&lt;/i&gt; Mutation-Positive Solid Tumors
2,026
2026-08-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Pasi A. Jänne, Melissa L. Johnson, Jin Li, Shubham Pant, Ulrich Dünzinger, Luis Ilia, Kerstin Möldner, Jae Eui Soh, Noboru Yamamoto
9
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.33143552
null
&lt;p&gt;Supplementary Figure S1: Geometric mean drug plasma concentration-time profiles of BI 1701963 QD after single and multiple administrations.&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1078-0432.33143543
10.1158/1078-0432.33143543
Supplementary Table S2 from The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with &lt;i&gt;KRAS&lt;/i&gt; Mutation-Positive Solid Tumors
2,026
2026-08-03
posted-content
American Association for Cancer Research (AACR)
null
null
null
null
null
null
Pasi A. Jänne, Melissa L. Johnson, Jin Li, Shubham Pant, Ulrich Dünzinger, Luis Ilia, Kerstin Möldner, Jae Eui Soh, Noboru Yamamoto
9
null
0
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.1158/1078-0432.33143543
null
&lt;p&gt;Supplementary Table S2: Representativeness of study participants with KRAS mutation-positive solid tumors&lt;/p&gt;
null
null
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.1158/1557-3125.ras18-ia19
10.1158/1557-3125.ras18-ia19
Abstract IA19: Insight towards therapeutic susceptibility of KRAS-mutant cancers from MRTX1257, a novel KRAS G12C mutant-selective small-molecule inhibitor
2,020
2020-05-01
journal-article
American Association for Cancer Research (AACR)
Molecular Cancer Research
18
5_Supplement
IA19-IA19
1541-7786, 1557-3125
null
James G. Christensen
1
Mirati Therapeutics, San Diego, CA.
0
0
true
null
null
null
https://doi.org/10.1158/1557-3125.ras18-ia19
https://aacrjournals.org/mcr/article/18/5_Supplement/IA19/233844/Abstract-IA19-Insight-towards-therapeutic
Abstract The ability to effectively target mutated KRAS has remained elusive despite decades of research. By solving a highly informative set of ligand-complexed co-crystal structures coupled with iterative structure-based drug design, substituted tetrahydropyridopyrimidines were identified as selective, covalent inhib...
null
en
qo8UvdggP3AX1mbfD
gjZobmodLEvlFmgXK
10.2139/ssrn.5205537
10.2139/ssrn.5205537
Emergent Sentience in Large Language Models Emergent Sentience in Large Language Models: Transformer Architecture and the Neurological Foundations of Consciousness
2,025
2025
posted-content
Elsevier BV
null
null
null
null
null
null
Michael Rivera
1
null
0
20
false
null
null
null
https://doi.org/10.2139/ssrn.5205537
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.5220/0012960200004508
10.5220/0012960200004508
Comparison and Analysis of Large Language Models Based on Transformer
2,024
2024
proceedings-article
SCITEPRESS - Science and Technology Publications
Proceedings of the 1st International Conference on Engineering Management, Information Technology and Intelligence
null
null
597-602
null
null
Yingying Chang
1
School of Information and Management Sciences, Henan Agricultural University, Zhengzhou, China, --- Select a Country ---
0
0
false
null
null
null
https://doi.org/10.5220/0012960200004508
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-2733-4_2
10.1007/979-8-8688-2733-4_2
Inside the Transformer: Core Architectures
2,026
2026
book-chapter
Apress
Mastering Large Language Models
null
null
33-76
null
9798868827327, 9798868827334
Ajay Rawat, Vardan Pathak
2
null
0
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-2733-4_2
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.2139/ssrn.6199178
10.2139/ssrn.6199178
Security and Risk Implications of Transformer-Based Large Language Models
2,026
2026
posted-content
Elsevier BV
null
null
null
null
null
null
Sergey Saburov
1
null
0
0
false
null
null
null
https://doi.org/10.2139/ssrn.6199178
null
The growing adoption of Large Language Models (LLMs) across a wide range of applications has introduced new challenges in application security, complementing traditional deterministic software approaches rather than replacing them entirely. While this transition enables advanced capabilities in automated reasoning and ...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.4018/979-8-3373-2038-0.ch005
10.4018/979-8-3373-2038-0.ch005
Transformative Role of Transformer Models in Healthcare
2,025
2025-08-29
book-chapter
IGI Global Scientific Publishing
Transformative Role of Transformer Models in Healthcare
null
null
123-160
null
9798337320380, 9798337320403
Deepa Lakshmi S.
1
PG & Research Department of Computer Science, Dwaraka Doss Goverdhan Doss Vaishnav College, India
0
0
true
null
null
null
https://doi.org/10.4018/979-8-3373-2038-0.ch005
null
Artificial Intelligence (AI) is a field of computer science that enables machines to learn, interpret, and make decisions like humans. In healthcare, AI is driving transformation by introducing systems that simulate human behavior and reasoning. The sector produces vast amounts of structured and unstructured data. AI t...
null
ng
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.20944/preprints202602.0680.v1
10.20944/preprints202602.0680.v1
Security and Risk Implications of Transformer-Based Large Language Models
2,026
2026-02-09
posted-content
MDPI AG
null
null
null
null
null
null
Sergey Saburov
1
null
0
0
true
http://creativecommons.org/licenses/by/4.0
null
null
https://doi.org/10.20944/preprints202602.0680.v1
null
The growing adoption of Large Language Models (LLMs) across a wide range of applications has introduced new challenges in application security, complementing traditional deterministic software approaches rather than replacing them entirely. While this transition enables advanced capabilities in automated reasoning and ...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.21203/rs.3.rs-4640131/v1
10.21203/rs.3.rs-4640131/v1
AI Content Self-Detection for Transformer-based large Language Models
2,024
2024-07-31
posted-content
Springer Science and Business Media LLC
null
null
null
null
null
null
Antonio Caiado, Michael Hahsler
2
Southern Methodist University
2
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.21203/rs.3.rs-4640131/v1
null
Abstract The usage of generative artificial intelligence (AI)tools based on large language models, including ChatGPT, Bard, and Claude, for text generation, has many exciting applications with the potential for phenomenal productivity gains. One issue is authorship attribution when using AI tools. This is especially im...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.36227/techrxiv.171925719.97800486/v1
10.36227/techrxiv.171925719.97800486/v1
Mathematical Foundations of Hallucination in Transformer-Based Large Language Models for Improvisation
2,024
2024-06-24
posted-content
Institute of Electrical and Electronics Engineers (IEEE)
null
null
null
null
null
null
Ahmet Gundogmusler, Fatma Bayindiroglu, Mustafa Karakucukoglu
3
null
1
0
true
https://creativecommons.org/licenses/by-nc-sa/4.0/
null
null
https://doi.org/10.36227/techrxiv.171925719.97800486/v1
null
Transformer architectures have revolutionized natural language processing through their ability to handle longrange dependencies and generate contextually coherent text. Despite their impressive capabilities, these models frequently produce outputs that are not directly grounded in the input data, a phenomenon known as...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.36227/techrxiv.171865245.51607046/v1
10.36227/techrxiv.171865245.51607046/v1
Mathematical Foundations of Hallucination in Transformer-Based Large Language Models for Improvisation
2,024
2024-06-17
posted-content
Institute of Electrical and Electronics Engineers (IEEE)
null
null
null
null
null
null
Ahmet Gundogmusler, Fatma Bayindiroglu, Mustafa Karakucukoglu
3
null
2
0
true
https://creativecommons.org/licenses/by-nc-sa/4.0/
null
null
https://doi.org/10.36227/techrxiv.171865245.51607046/v1
null
Transformer architectures have revolutionized natural language processing through their ability to handle longrange dependencies and generate contextually coherent text. Despite their impressive capabilities, these models frequently produce outputs that are not directly grounded in the input data, a phenomenon known as...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.36227/techrxiv.173610898.84404151/v1
10.36227/techrxiv.173610898.84404151/v1
A Systematic Review on Optimization Approaches for Transformer and Large Language Models
2,025
2025-01-05
posted-content
Institute of Electrical and Electronics Engineers (IEEE)
null
null
null
null
null
null
Atefeh Hemmati, Fatemeh Bazikar, Amir Masoud Rahmani, Hossein Moosaei
4
Department of Computer Engineering, Science and Research Branch, Islamic Azad University
2
0
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.36227/techrxiv.173610898.84404151/v1
null
Large language models (LLMs) are deep learning (DL) algorithms that can perform a range of natural language processing (NLP) tasks. LLMs use transformer models trained using large datasets and have revolutionized NLP tasks. However, their large-scale implementation poses significant computational resources, efficiency,...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.20944/preprints202410.1348.v1
10.20944/preprints202410.1348.v1
Investigating the Predominance of Large Language Models in Low-Resource Bangla Language Over Transformer Models for Hate Speech Detection: A Comparative Analysis
2,024
2024-10-17
posted-content
MDPI AG
null
null
null
null
null
null
Fatema Tuj Johora Faria, Laith H. Baniata, Sangwoo Kang
3
null
3
0
true
http://creativecommons.org/licenses/by/4.0
null
null
https://doi.org/10.20944/preprints202410.1348.v1
null
The rise of abusive language on social media is a significant threat to mental health and 1 social cohesion. For Bengali speakers, the need for effective detection is critical. However, current 2 methods fall short in addressing the massive volume of content. Improved techniques are urgently 3 needed to combat online h...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.36227/techrxiv.173337226.68077827/v1
10.36227/techrxiv.173337226.68077827/v1
Contextual Pathway Reconfiguration for Efficient Multimodal Understanding in Transformer-based Large Language Models
2,024
2024-12-05
posted-content
Institute of Electrical and Electronics Engineers (IEEE)
null
null
null
null
null
null
Michael Kobrun, Jacob Fitzwilliam, Isabella Montmorency, Alexander Krajewski, Edward Sandringham
5
null
0
0
true
https://creativecommons.org/licenses/by-nc-sa/4.0/
null
null
https://doi.org/10.36227/techrxiv.173337226.68077827/v1
null
Contextual pathway reconfiguration introduces a dynamic approach to enhancing the performance and adaptability of transformer-based architectures in multimodal settings. By incorporating hierarchical gating mechanisms and auxiliary embedding layers, the proposed framework efficiently prioritizes and synthesizes informa...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.7551/mitpress/15517.003.0003
10.7551/mitpress/15517.003.0003
Large Language Models
2,025
2025-10-28
book-chapter
The MIT Press
Large Language Models
null
null
1-18
null
9780262383523
null
0
null
7
0
true
null
null
null
https://doi.org/10.7551/mitpress/15517.003.0003
https://direct.mit.edu/books/book/chapter-pdf/2560640/c000400_9780262383523.pdf
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1109/fllm67465.2025.11391180
10.1109/fllm67465.2025.11391180
Automating Sarcasm Identification from App Reviews Using Transformer-based Language Models
2,025
2025-11-25
proceedings-article
IEEE
2025 3rd International Conference on Foundation and Large Language Models (FLLM)
null
null
1116-1118
null
null
Khubaib Amjad Alam, Bisma Shahid, Muhammad Haroon, Qaisar Shafi, Momina Kamal Cheema
5
Al Ain University,College of Engineering,United Arab Emirates
0
8
true
https://doi.org/10.15223/policy-029
null
null
https://doi.org/10.1109/fllm67465.2025.11391180
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-2297-1_9
10.1007/979-8-8688-2297-1_9
Transformer Block and Full Transformer Model—It’s Time to Put the Puzzle Together
2,026
2026
book-chapter
Apress
Building Large Language Models from Scratch
null
null
325-366
null
9798868822964, 9798868822971
Dilyan Grigorov
1
null
0
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-2297-1_9
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.31219/osf.io/k495f
10.31219/osf.io/k495f
Semantic Layer Reconstruction in Large Language Models Using Multi-Level Transformer Feedback Mechanisms
2,024
2024-12-05
posted-content
Center for Open Science
null
null
null
null
null
null
Charles Welling, Beatrix Longborough, Barnaby Winterbourne, Isabella Eisenhardt
4
null
0
0
true
https://creativecommons.org/licenses/by/4.0/legalcode
null
null
https://doi.org/10.31219/osf.io/k495f
null
Semantic Layer Reconstruction introduces a transformative mechanism for refining the interactions between transformer layers, leveraging recursive feedback to enhance semantic coherence across linguistic tasks. The framework incorporates a multi-level feedback mechanism that recalibrates token embeddings through bidire...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1109/iisec59749.2023.10391040
10.1109/iisec59749.2023.10391040
Enhancing Text Summarization: Evaluating Transformer-Based Models and the Role of Large Language Models like ChatGPT
2,023
2023-12-21
proceedings-article
IEEE
2023 4th International Informatics and Software Engineering Conference (IISEC)
null
null
1-4
null
null
Pınar Savcı, Bihter Das
2
Ar&#x00E7;elik A.&#x015E;.,Istanbul,Turkey
4
16
true
https://doi.org/10.15223/policy-029
null
null
https://doi.org/10.1109/iisec59749.2023.10391040
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.31219/osf.io/7qbsa_v1
10.31219/osf.io/7qbsa_v1
Contextual Residual Inversion in Transformer-Based Large Language Models: A Reversibility Paradigm for Studying Representational Fidelity
2,025
2025-03-24
posted-content
Center for Open Science
null
null
null
null
null
null
Daniel Arthev, Richard Abercrombie, Clive Fenwick
3
null
0
0
true
https://creativecommons.org/licenses/by/4.0/legalcode
null
null
https://doi.org/10.31219/osf.io/7qbsa_v1
null
Contextual Residual Inversion introduces a theoretical and computational approach for estimating partial reversibility of internal residual streams in transformer-based LLMs through non-invasive linear inversion operators applied to frozen inference passes. The method defines invertibility over structured prompt famili...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.22541/au.173145004.42488699/v1
10.22541/au.173145004.42488699/v1
Dynamic Probabilistic Contextual Realignment in Transformer-Based Large Language Models for Semantic Consistency
2,024
2024-11-12
posted-content
Wiley
null
null
null
null
null
null
Yukito Odorico, Kousuke Hayashi, Isamu Kiryu, Kenta Yamagata, Daiki Masuda, Shohei Shinohara
6
null
0
0
true
https://creativecommons.org/licenses/by-nc-sa/4.0/
null
null
https://doi.org/10.22541/au.173145004.42488699/v1
null
The rapid evolution of artificial intelligence has led to the development of sophisticated language models capable of generating human-like text. However, maintaining semantic consistency throughout extended text generation remains a significant challenge. Introducing Dynamic Probabilistic Contextual Realignment (DPCR)...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1109/fllm63129.2024.10852494
10.1109/fllm63129.2024.10852494
Enhancing Named Entity Recognition in Arabic: Leveraging Transformer-Based Models and Open Data Sources
2,024
2024-11-26
proceedings-article
IEEE
2024 2nd International Conference on Foundation and Large Language Models (FLLM)
null
null
357-361
null
null
Faiza Belbachir, Assia Soukane
2
Laboratoire de Recherche LYRIDS,Ecole d&#x2019;ing&#x00E9;nieurs Campus de Paris (ECE),Paris,France
2
0
true
https://doi.org/10.15223/policy-029
null
null
https://doi.org/10.1109/fllm63129.2024.10852494
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.18653/v1/2024.clinicalnlp-1.16
10.18653/v1/2024.clinicalnlp-1.16
Conversational Topic Recommendation in Counseling and Psychotherapy with Decision Transformer and Large Language Models
2,024
2024
proceedings-article
Association for Computational Linguistics
Proceedings of the 6th Clinical Natural Language Processing Workshop
null
null
196-201
null
null
Aylin Gunal, Baihan Lin, Djallel Bouneffouf
3
null
5
0
false
null
null
null
https://doi.org/10.18653/v1/2024.clinicalnlp-1.16
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-2785-3_3
10.1007/979-8-8688-2785-3_3
Advanced Transformer Architectures
2,026
2026
book-chapter
Apress
Transformers and Large Language Models
null
null
123-183
null
9798868827846, 9798868827853
Ahmed Fawzy Gad
1
null
0
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-2785-3_3
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-0515-8_1
10.1007/979-8-8688-0515-8_1
Introduction to Large Language Models with OpenAI
2,024
2024
book-chapter
Apress
Large Language Models Projects
null
null
3-29
null
9798868805141, 9798868805158
Pere Martra
1
null
0
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-0515-8_1
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-2216-2_7
10.1007/979-8-8688-2216-2_7
Unpacking the Transformer Architecture
2,025
2025
book-chapter
Apress
The Practical Guide to Large Language Models
null
null
295-348
null
9798868822155, 9798868822162
Ivan Gridin
1
null
0
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-2216-2_7
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1109/i3ctcon68242.2026.11507131
10.1109/i3ctcon68242.2026.11507131
Context-Aware Transformer Optimization for Improved Generalization in Large Language Models
2,026
2026-03-14
proceedings-article
IEEE
2026 IEEE International Conference for Convergence in Computing Technology (I3CTCON)
null
null
1-6
null
null
Santosh Datta Bompally
1
Webster University,Independent Security Researcher,MO,63119
0
20
true
https://doi.org/10.15223/policy-029
null
null
https://doi.org/10.1109/i3ctcon68242.2026.11507131
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.3905/jfds.2025.1.198
10.3905/jfds.2025.1.198
Quantitative Models with Qualitative Scenarios: Simulation with Transformer and Large Language Models
2,025
2025-07-31
journal-article
With Intelligence LLC
The Journal of Financial Data Science
7
3
116-131
2640-3943
null
Irene Aldridge, Daham Kim
2
null
0
0
true
null
null
null
https://doi.org/10.3905/jfds.2025.1.198
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.3390/electronics15142988
10.3390/electronics15142988
Hierarchical Classification of Arabic Legal Cases Using Transformer Architectures and Large Language Models
2,026
2026-07-08
journal-article
MDPI AG
Electronics
15
14
2988
2079-9292
null
Nourah Alangari, Nouf Alshenaifi, Huda Almuzaini
3
Computer Science Department, College of Computer and Information Sciences, King Saud University, Riyadh 11543, Saudi Arabia
0
26
true
https://creativecommons.org/licenses/by/4.0/
null
null
https://doi.org/10.3390/electronics15142988
null
Automated classification of Arabic legal texts presents unique challenges stemming from the formal register of judicial language, domain-specific Sharī‘a terminology, and the severe class imbalance inherent in hierarchical legal taxonomies. This paper addresses these challenges through a systematic investigation of hie...
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-2733-4_1
10.1007/979-8-8688-2733-4_1
Introduction to Large Language Models
2,026
2026
book-chapter
Apress
Mastering Large Language Models
null
null
3-31
null
9798868827327, 9798868827334
Ajay Rawat, Vardan Pathak
2
null
0
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-2733-4_1
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.5220/0012717200003756
10.5220/0012717200003756
Artificial Intelligence-Powered Large Language Transformer Models for Opioid Abuse and Social Determinants of Health Detection for the Underserved Population
2,024
2024
proceedings-article
SCITEPRESS - Science and Technology Publications
Proceedings of the 13th International Conference on Data Science, Technology and Applications
null
null
15-26
null
null
Don Roosan, Yanting Wu, Jay Chok, Christopher Sanine, Tiffany Khou, Yawen Li, Hasiba Khan
7
Western University of Health Sciences, College of Pharmacy, 309 E 2nd Street, Pomona, CA, U.S.A.
9
0
false
null
null
null
https://doi.org/10.5220/0012717200003756
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.18653/v1/2025.xllm-1.10
10.18653/v1/2025.xllm-1.10
Seamlessly Integrating Tree-Based Positional Embeddings into Transformer Models for Source Code Representation
2,025
2025
proceedings-article
Association for Computational Linguistics
Proceedings of the 1st Joint Workshop on Large Language Models and Structure Modeling (XLLM 2025)
null
null
91-98
null
null
Patryk Bartkowiak, Filip Graliński
2
null
0
0
false
null
null
null
https://doi.org/10.18653/v1/2025.xllm-1.10
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/978-3-031-76646-6_26
10.1007/978-3-031-76646-6_26
In the Engine Room: Transformer Models
2,025
2025
book-chapter
Springer Nature Switzerland
Synthesis Lectures on Human-Centered Informatics
null
null
193-202
1946-7680, 1946-7699
9783031766459, 9783031766466
Clayton Lewis
1
null
0
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/978-3-031-76646-6_26
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-0540-0_2
10.1007/979-8-8688-0540-0_2
What Are Large Language Models?
2,024
2024
book-chapter
Apress
Introduction to Python and Large Language Models
null
null
59-100
null
9798868805394, 9798868805400
Dilyan Grigorov
1
null
2
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-0540-0_2
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.31219/osf.io/bj7xc_v1
10.31219/osf.io/bj7xc_v1
Large Language Models with Novel Token Processing Architecture: A Study of the Dynamic Sequential Transformer
2,024
2024-10-22
posted-content
Center for Open Science
null
null
null
null
null
null
Kusi Men, Na Pin, Shumei Lu, Qian Zhang, Huanhuan Wang
5
null
0
0
true
https://creativecommons.org/licenses/by/4.0/legalcode
null
null
https://doi.org/10.31219/osf.io/bj7xc_v1
null
The increasing complexity and scale of language models have introduced significant challenges related to computational efficiency, inference speed, and the generation of factually accurate responses. Addressing these issues, a novel architectural enhancement known as the Dynamic Sequential Transformer (DST) has been pr...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1201/9781003474173-5
10.1201/9781003474173-5
Deep Learning Transformer Architecture
2,024
2024-05-28
book-chapter
Chapman and Hall/CRC
Artificial Intelligence and Large Language Models
null
null
153-190
null
9781003474173
Kutub Thakur, Helen G. Barker, Al-Sakib Khan Pathan
3
null
0
0
false
null
null
null
https://doi.org/10.1201/9781003474173-5
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.2139/ssrn.5175593
10.2139/ssrn.5175593
Construction of Collaborative Intelligent Manufacturing Agents For Special Transformer Coil Workshop Based on Large Language Models And Digital Twins
2,025
2025
posted-content
Elsevier BV
null
null
null
null
null
null
Xuedong Zhang, Wenlei Sun, Ke Chen, Renben Jiang
4
null
0
0
false
null
null
null
https://doi.org/10.2139/ssrn.5175593
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.5220/0014649700004058
10.5220/0014649700004058
Large Language Models for Quality Control of Large Language Models
2,026
2026
proceedings-article
SCITEPRESS - Science and Technology Publications
Proceedings of the 14th International Conference on Model-Based Software and Systems Engineering
null
null
150-161
null
null
Preethika Chandrasekaran, Imron Shajahan, Saran Sankaran, Benjamin Nast, Kurt Sandkuhl
5
Institute of Computer Science, University of Rostock, Albert-Einstein-Str. 22, 18059 Rostock, Germany
0
0
false
null
null
null
https://doi.org/10.5220/0014649700004058
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1109/acet67282.2025.11430384
10.1109/acet67282.2025.11430384
On the Interpretability of Transformer Based Large Language Models
2,025
2025-11-21
proceedings-article
IEEE
2025 2nd International Conference on Advanced Computing and Emerging Technologies (ACET)
null
null
1-6
null
null
Aarush Sharma, Lavika Goel, VK Panchal
3
Meerut institute of engineering and technology,Computer Science and Engineering,Meerut,India
0
10
true
https://doi.org/10.15223/policy-029
null
null
https://doi.org/10.1109/acet67282.2025.11430384
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1038/s41598-026-43507-7
10.1038/s41598-026-43507-7
Transparent AI for mathematics: transformer-based large language models for mathematical entity relationship extraction with XAI
2,026
2026-03-11
journal-article
Springer Science and Business Media LLC
Scientific Reports
16
1
null
2045-2322
null
Tanjim Taharat Aurpa
1
null
0
35
true
https://creativecommons.org/licenses/by-nc-nd/4.0
null
null
https://doi.org/10.1038/s41598-026-43507-7
https://www.nature.com/articles/s41598-026-43507-7.pdf
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1201/9781003517245-3
10.1201/9781003517245-3
Large Language Models
2,024
2024-08-20
book-chapter
CRC Press
Large Language Models
null
null
70-108
null
9781003517245
John Atkinson-Abutridy
1
null
0
0
false
null
null
null
https://doi.org/10.1201/9781003517245-3
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1101/2025.01.28.635344
10.1101/2025.01.28.635344
Database-Augmented Transformer-Based Large Language Models Achieve High Accuracy in Mapping Gene-Phenotype Relationships
2,025
2025-02-01
posted-content
openRxiv
null
null
null
null
null
null
Nicolas Matthew Suhardi, Anastasia Oktarina, Mathias P.G. Bostrom, Xu Yang, Vincentius Jeremy Suhardi
5
Skeletal Health and Orthopedic Research Program, Hospital for Special Surgery, New York, NY 10021, USA
0
26
true
https://www.biorxiv.org/about/FAQ#license
null
null
https://doi.org/10.1101/2025.01.28.635344
null
Abstract Transformer-based large language models (LLMs) have demonstrated significant potential in the biological and medical fields due to their ability to effectively learn from large-scale, diverse datasets and perform a wide range of downstream tasks. However, LLMs are limited by issues such as information processi...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.2139/ssrn.5149339
10.2139/ssrn.5149339
The Mathematics of Large Language Diffusion Models versus Large Language Autoregressive Models
2,025
2025
posted-content
Elsevier BV
null
null
null
null
null
null
Miquel Noguer I Alonso
1
null
0
0
false
null
null
null
https://doi.org/10.2139/ssrn.5149339
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-0515-8_4
10.1007/979-8-8688-0515-8_4
Evaluating Models
2,024
2024
book-chapter
Apress
Large Language Models Projects
null
null
133-190
null
9798868805141, 9798868805158
Pere Martra
1
null
0
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-0515-8_4
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-0515-8
10.1007/979-8-8688-0515-8
Large Language Models Projects
2,024
2024
book
Apress
null
null
null
null
null
9798868805141, 9798868805158
Pere Martra
1
null
2
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-0515-8
https://link.springer.com/content/pdf/10.1007/979-8-8688-0515-8.pdf
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.36548/jiip.2025.2.005
10.36548/jiip.2025.2.005
Improving Narrative Coherence in Dense Video Captioning through Transformer and Large Language Models
2,025
2025-06-03
journal-article
Inventive Research Organization
Journal of Innovative Image Processing
7
2
333-361
2582-4252
null
Dvijesh Bhatt, Priyank Thakkar
2
Department of Computer Science and Engineering, Institute of Technology, Nirma University, Ahmedabad
3
53
true
null
null
null
https://doi.org/10.36548/jiip.2025.2.005
https://irojournals.com/iroiip/article/download/783/696
Dense video captioning aims to identify events within a video and generate natural language descriptions for each event. Most existing approaches adhere to a two-stage framework consisting of an event proposal module and a caption generation module. Previous methodologies have predominantly employed convolutional neura...
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/979-8-8688-0540-0_1
10.1007/979-8-8688-0540-0_1
Evolution and Significance of Large Language Models
2,024
2024
book-chapter
Apress
Introduction to Python and Large Language Models
null
null
1-57
null
9798868805394, 9798868805400
Dilyan Grigorov
1
null
1
0
true
https://www.springernature.com/gp/researchers/text-and-data-mining
null
null
https://doi.org/10.1007/979-8-8688-0540-0_1
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1109/isscc49657.2024.10454330
10.1109/isscc49657.2024.10454330
20.5 C-Transformer: A 2.6-18.1μJ/Token Homogeneous DNN-Transformer/Spiking-Transformer Processor with Big-Little Network and Implicit Weight Generation for Large Language Models
2,024
2024-02-18
proceedings-article
IEEE
2024 IEEE International Solid-State Circuits Conference (ISSCC)
null
null
368-370
null
null
Sangyeob Kim, Sangjin Kim, Wooyoung Jo, Soyeon Kim, Seongyon Hong, Hoi-Jun Yoo
6
Korea Advanced Institute of Science and Technology,Daejeon,Korea
39
9
true
https://doi.org/10.15223/policy-029
null
null
https://doi.org/10.1109/isscc49657.2024.10454330
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1145/3644116.3644226
10.1145/3644116.3644226
Research and Application of Large Language Models in HealthcareCurrent Development of Large Language Models in the Healthcare FieldA Framework for Applying Large Language Models and the Opportunities and Challenges of Large Language Models in Healthcare: A Framework for Applying Large Language Models and the Opportunit...
2,023
2023-10-20
proceedings-article
ACM
Proceedings of the 2023 4th International Symposium on Artificial Intelligence for Medicine Science
null
null
664-670
null
null
Chunfang Zhou, Qingyue Gong, Jinyang Zhu, Huidan Luan
4
School of Artificial Intelligence and Information Technology, Nanjing University of Chinese Medicine, China
1
45
true
https://www.acm.org/publications/policies/copyright_policy#Background
null
null
https://doi.org/10.1145/3644116.3644226
null
null
null
null
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1007/978-981-95-1050-4_18
10.1007/978-981-95-1050-4_18
Symbolic Constraint-Solving Capabilities of Transformer Large Language Models
2,026
2026
book-chapter
Springer Nature Singapore
Proceedings of 1st GENZERO Workshop
null
null
147-154
null
9789819510498, 9789819510504
Leyan Pan, Chris Esposo, Jacob Abernethy, Vijay Ganesh, Wenke Lee
5
null
0
5
true
https://creativecommons.org/licenses/by/4.0
Technology Innovation Institute (TII) - Abu Dhabi
null
https://doi.org/10.1007/978-981-95-1050-4_18
null
Abstract The empirical success of Transformer-based Large Language Models (LLMs) has elicited significant interest in their application for security domains such as formal verification and program analysis. However, their application in formal domains, such as formal verification and program analysis, is constrained by...
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1201/9781003669012-4
10.1201/9781003669012-4
Large Language Models in Chemistry
2,025
2025-12-18
book-chapter
CRC Press
Large Language Models for Chemists
null
null
49-67
null
9781003669012
Zhiling Zheng
1
null
0
0
false
null
null
null
https://doi.org/10.1201/9781003669012-4
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK
10.1201/9781003595533-3
10.1201/9781003595533-3
Large Language Models
2,025
2025-02-27
book-chapter
Chapman and Hall/CRC
Concept Drift in Large Language Models
null
null
14-22
null
9781003595533
Ketan Sanjay Desale
1
null
0
0
false
null
null
null
https://doi.org/10.1201/9781003595533-3
null
null
null
en
sXpd57pG3k5WBybtZ
qfe2K10al8pHlHiyK